Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27491907 | 0.98 | SMN1; SMN2 (0.61) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL19313223 | 0.95 | MAPT (0.62) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| Adipic Acid SCHEMBL272108 | 0.91 | MAPT (0.55) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25342051 | 0.91 | HDAC3 (0.76) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| Phenylbutanoic Acid SCHEMBL724890 | 0.89 | HDAC1 (0.81) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| Adipic Acid SCHEMBL5694409 | 0.89 | MAPT (0.53) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2016247 | 0.89 | KEAP1 (0.61) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL31273986 | 0.89 | KEAP1 (0.61) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29010038 | 0.86 | SMN1; SMN2 (0.63) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| Phenyl Propionic Acid SCHEMBL6660445 | 0.86 | KEAP1 (0.68) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011038469-A1 | SUPPRESSIVE AGENTS | PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010088729-A1 | COMPOSITIONS AND USES THEREFOR | UNIVERSITY OF TASMANIA THROUGH THE MENZIES RESEARCH INSTITUTE (AU) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010022444-A1 | METHODS AND AGENTS FOR MODULATING KINASE SIGNALLING PATHWAYS THROUGH MODULATION OF MIXED-LINEAGE KINASE DOMAIN-LIKE PROTEIN (MLKL) | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2010-03-04 | — | — | WO | disclosed |
| US-20090215669-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | DIA-B TECH LIMITED (AU) | 2009-08-27 | — | — | US | disclosed |
| WO-2009021289-A1 | POTASSIUM CHANNEL INHIBITORS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-02-19 | — | — | WO | disclosed |
| EP-1962882-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | Dia-B Tech Limited (AU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008025069-A1 | METHODS OF MODULATING CELLULAR ACTIVITY AND COMPOSITIONS THEREFOR | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-03-06 | — | — | WO | disclosed |
| US-20070197430-A1 | Conjugates And Therapeutic Uses Thereof | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-08-23 | — | — | US | disclosed |
| WO-2007059569-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES | DIA-B TECH LIMITED (AU) | 2007-05-31 | — | — | WO | disclosed |
| EP-1781689-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | The Walter and Eliza Hall Institute of Medical Research (AU) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007025332-A1 | A PEPTIDE AND ZINC ION COMPOSITION FOR TREATING DIABETES AND ENHANCING IMMUNE FUNCTION | DIA-B TECH LIMITED (AU) | 2007-03-08 | — | — | WO | disclosed |
| US-20070032417-A1 | Peptides and therapeutic uses thereof | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-02-08 | — | — | US | disclosed |
| WO-2006000034-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-05 | — | — | WO | disclosed |
| WO-2004058804-A1 | PEPTIDES AND THERAPEUTIC USES THEREOF | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-07-15 | — | — | WO | disclosed |
| CN-1074903-A | The six hydrogen azepine ketone and the tetrahydro benzo azepine ketone that replace | PFIZER (US) | 1993-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032417-A1 | Peptides and therapeutic uses thereof | BCL2, BAX, BCL2L13 | SMN1; SMN2 620/4885HDAC3 2168/4885HDAC4 2554/4885 |
| US-20070197430-A1 | Conjugates And Therapeutic Uses Thereof | BCL2, BAX, BAD | SMN1; SMN2 615/4885HDAC3 683/4885HDAC4 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.